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The difference in MACE numbers was 15 between the pla-
cebo group (n = 61) and escitalopram group (n = 46), in line
with the differences in depression remission. The difference
in MACE occurrence appearing beyond 1 year after random-
ization is a reasonable concern. However, a meta-analysis of
16 studies of depression following ACS found that differ-
ences in MACE occurrence became prominent after 1 year
and over longer follow-up intervals4; this is in keeping with
our findings, although we agree that further replication
should be sought.
Dr Zimmermann and colleagues raise concerns about the
cumulative incidence figures in the article. The data in Figure
2 have been rechecked, and we found that the cumulative
event curves were matched erroneously to the numbers at
risk. This was our mistake and an error that arose during the
revision process after the original submission and uncon-
nected to other analyses. The article has been corrected
online, and we apologize for the oversight. In addition, num-
bers at risk have also been revised for Figures 2 and 3, taking
into account the censoring date as well as end points. Regard-
ing mortality definitions, all-cause mortality was chosen as a
component of the MACE outcome at an early stage of proto-
col development, was recorded in the body of the protocol,
and was used in a prior publication2 as well as in the current
analysis. However, the change was not applied in the synop-
sis by mistake.
We appreciate Dr Rust’s concerns about placebo controls.
Because of the lack of evidence for the effect of depression
treatment shortly following ACS at the time the study was
designed, the EsDEPACS trial was judged both by funders
and by an independent ethics review panel to be addressing
an issue of clinical equipoise.5 In addition to providing study
drugs, research psychiatrists met with all participants
for at least 30 minutes at every visit and addressed psycho-
logical symptoms through supportive intervention as well as
promoting cardiac treatment. Participants could withdraw
from the trial for any reason. For participants without remis-
sion after the trial, further treatment was facilitated when
requested. All participants were approached for evaluation of
psychiatric outcomes 1 year after baseline evaluation.6 We
agree that findings from our studies3,5 support further active
control and stepwise intensification trials.
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Baseline Genotype Testing to Assess Drug
Resistance Before BeginningHIV Treatment
To the Editor In theupdatedRecommendations of the Interna-
tional Antiviral Society–USA Panel for the treatment and pre-
vention of human immunodeficiency virus (HIV) infection in
adults,1 the recommendations for laboratorymonitoringhave
been revised to include the use of baseline HIV genotype to
assess transmitted drug resistance. The panel recommended
testing only for nucleoside reverse transcriptase inhibitors,
nonnucleoside reverse transcriptase inhibitors, and protease
inhibitors, and reserved testing for integrase strand-transfer
inhibitor (InSTI) resistance to cases of suspected exposure to
a partner with InSTI resistance. All preferred regimens are
InSTI-based, favoringdolutegravir andbictegravir and,when
thosearenot available, raltegravir andelvitegravir/cobicistat.1
Although the transmission of signature mutations for
InSTIs (such as Y143R/C, N155H, or Q148K/R/H) is extremely
infrequent—henceweagree there is generallynoneed tomoni-
tor for these mutations prior to treatment initiation—there is
no rarity of InSTI polymorphisms that can reduce InSTI activ-
ity. Casadellà et al2 reported a 14% prevalence of such substi-
tutions in Europe on the basis of samples collected in treat-
ment-naive patients between 2006 and 2007. In our own
institution, prevalence was also 14% in treatment-naive
patients with acute or recent (<6 months postinfection) HIV
infection diagnosed in 2015 and 2016. The most frequently
found substitution was the E157Q polymorphism, and all pa-
tientswere infectedwith subtype B strains, suggesting that it
is unrelated to specific recombinant forms or subtypes.3
Antiretroviral-naivepatients carryingviruseswith suchapoly-
morphism have been reported to experience virologic failure
with raltegravir-4 and elvitegravir/cobicistat5–based regi-
mens. In fact, Charpentier et al5 reported that 2 of 8 antiret-
roviral-naivepatients startingelvitegravir/cobicistat–basedan-
tiretroviral treatment had experienced virologic failure.
In this context,webelieve that testingbaseline InSTIgeno-
typemight be considered inparticular epidemiologic settings
if such polymorphisms are reported to be frequent in a given
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population, region, or HIV risk group, particularly if raltegra-
vir or elvitegravir/cobicistat are the available or chosen In-
STIs. Regimenswith bictegravir or dolutegravir would not be
affected by such polymorphisms.
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In Reply As stated in the panel’s report,1 the relative absence
of resistance-conferringmutations for InSTIdrugssupports the
recommendation to not test routinely for InSTI resistance be-
fore start of HIV treatment. A summary of existing data re-
garding the relative lack of transmission of InSTI resistance–
conferring mutations was published this year.2
As discussed by Dr Ambrosioni and colleagues, the rela-
tively high prevalence of InSTI polymorphisms is of some
concern. We agree that it is worth monitoring the effect of
InSTI polymorphisms over time, especially as they may
potentially affect the efficacy of 2-drug, InSTI-based
therapy. To date, however, there are few data indicating that
these mutations have meaningful clinical effect on virologic
response, especially to InSTI agents recommended for ini-
tial therapy.
One of the main reasons the recommendations are up-
dated every 2 years is to incorporate new data that emerge re-
garding treatment of patients with and at risk for HIV infec-
tion. Since relevant and important data often emerge quickly
in this dynamic field, we are grateful to Ambrosioni and col-
leagues for putting this issue on the “watch list” for future rec-
ommendations.
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CORRECTION
Incorrect Data in Figures: In the Original Investigation entitled “Effect of Escit-
alopramvsPlaceboTreatment forDepressiononLong-termCardiacOutcomes in
PatientsWith Acute Coronary Syndrome: A Randomized Clinical Trial,” published
in the July 24/31, 2018, issue of JAMA,1 errors occurred in figures. In Figure 2, in-
correct data curveswere published in the graph, and in Figures 2 and 3, incorrect
numbers at risk were shown. This article has been corrected online.
1. Kim JM, Stewart R, Lee YS, et al. Effect of escitalopram vs placebo treatment
for depression on long-term cardiac outcomes in patients with acute coronary
syndrome: a randomized clinical trial. JAMA. 2018;320(4):350-358. doi:10.1001
/jama.2018.9422
Unclear Sentence and Incorrect Number in Figure: The Research Letter en-
titled “Lethality of Civilian Active Shooter Incidents With andWithout Semiauto-
matic Rifles in the United States,”1 published in the September 11, 2018, issue of
JAMA, contained an unclear sentence. The second sentence should have been
worded as follows: “Many weapons were banned in 1994 under the federal as-
sault weapons ban but were reintroduced to the public marketplace in 2004.” In
addition, the Figure should have reported the number of active shooter incidents
with a semiautomatic rifle as n = 61. This article was corrected online.
1. de Jager E, Goralnick E, McCarty JC, Hashmi ZG, JarmanMP, Haider AH.
Lethality of civilian active shooter incidents with and without semiautomatic
rifles in the United States. JAMA. 2018;320(10):1034-1035. doi:10.1001/jama
.2018.11009
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